Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
Year: 2019
Type: article
Source: Annals of Oncology
Institutions: Justus-Liebig-Universität Gießen, Universitätsklinikum Gießen und Marburg, Roswell Park Comprehensive Cancer Center, University at Buffalo, State University of New York, Emory University, Children's Healthcare of Atlanta, The Barbara Ann Karmanos Cancer Institute, Merck & Co., Inc., Rahway, NJ, USA (United States), Weill Cornell Medicine
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2990440775